Literature DB >> 16113995

Enantioselective binding to the human organic cation transporter-1 (hOCT1) determined using an immobilized hOCT1 liquid chromatographic stationary phase.

R Moaddel1, S Patel, K Jozwiak, R Yamaguchi, P C Ho, I W Wainer.   

Abstract

A liquid chromatography stationary phase containing immobilized membranes obtained from a cell line that expresses the human organic cation transporter (hOCT1-IAM) has been used to study the binding of the enantiomers of propranolol, atenolol, pseudoephedrine, and alpha-methylbenzylamine to the immobilized hOCT1. Frontal displacement chromatography was used to determine the binding affinities (K(d) values), and the data demonstrate that there was an enantioselective difference in the K(d) values of the enantiomers of propranolol, atenolol, and pseudoephedrine, while alpha-methylbenzylamine did not significantly bind to the transporter. Competitive inhibition studies with the cell line used to create the chromatographic column demonstrated that, for the enantiomers of propranolol, the ratio of the chromatographically determined K(d) values [K(d (+)-(R)-propranolol)/K(d (-)-(S)-propranolol) = 2.98] reflected an enantioselective difference in the functional activity of the two enantiomers [IC(50 (+)-(R)-propranolol)/IC(50 (-)-(S)-propranolol) = 2.75]. The chromatographically determined K(d) values were used to construct an initial pharmacophore which contains a hydrogen bond donating site that appears to be responsible for the observed enantioselectivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113995     DOI: 10.1002/chir.20195

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  9 in total

1.  Stereoselective binding of chiral ligands to single nucleotide polymorphisms of the human organic cation transporter-1 determined using cellular membrane affinity chromatography.

Authors:  R Moaddel; F Bighi; R Yamaguchi; S Patel; S Ravichandran; I W Wainer
Journal:  Anal Biochem       Date:  2010-03-03       Impact factor: 3.365

Review 2.  Determination and modelling of stereoselective interactions of ligands with drug transporters: a key dimension in the understanding of drug disposition.

Authors:  P Bhatia; M Kolinski; R Moaddel; K Jozwiak; I W Wainer
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

3.  Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1).

Authors:  R Moaddel; S Ravichandran; F Bighi; R Yamaguchi; I W Wainer
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

4.  Investigation of molecular recognition in biological systems using cellular membrane affinity chromatography.

Authors:  Irving W Wainer
Journal:  Chim Oggi       Date:  2008-09

5.  Exploring enantiospecific ligand-protein interactions using cellular membrane affinity chromatography: chiral recognition as a dynamic process.

Authors:  Krzysztof Jozwiak; Ruin Moaddel; Sarangan Ravichandran; Anita Plazinska; Joanna Kozak; Sharvil Patel; Rika Yamaguchi; Irving W Wainer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-01       Impact factor: 3.205

6.  Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).

Authors:  Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-11-11       Impact factor: 3.000

7.  Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

Authors:  Anne T Nies; Ute Hofmann; Claudia Resch; Elke Schaeffeler; Maria Rius; Matthias Schwab
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

Review 8.  Enantioselective Drug Recognition by Drug Transporters.

Authors:  Yuichi Uwai
Journal:  Molecules       Date:  2018-11-22       Impact factor: 4.411

9.  OCT1 Polyspecificity-Friend or Foe?

Authors:  Marleen J Meyer; Mladen V Tzvetkov
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.